Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC

BACKGROUND: In non-small cell lung cancer (NSCLC), platelet-derived growth factor receptor (PDGFR) mediates angiogenesis, tissue invasion, and tumor interstitial pressure. Olaratumab (IMC-3G3) is a fully human anti-PDGFRα monoclonal antibody. This Phase II study assessed safety and efficacy of olara...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer
Main Authors: Gerber, David E., Swanson, Paul, Lopez-Chavez, Ariel, Wong, Lucas, Dowlati, Afshin, Pennell, Nathan A., Cronier, Damien M., Qin, Amy, Ilaria, Robert, Cosaert, Jan, Shahir, Ashwin, Baggstrom, Maria Q.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672830/
https://ncbi.nlm.nih.gov/pubmed/28838379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2017.07.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados